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Abstract
Background: Basal breast cancers (BCs) represent ~15% of BCs. Although overall poor, prognosis is heterogeneous.
Identification of good- versus poor-prognosis patients is difficult or impossible using the standard histoclinical
features and the recently defined prognostic gene expression signatures (GES). Kinases are often activated or
overexpressed in cancers, and constitute targets for successful therapies. We sought to define a prognostic model
of basal BCs based on kinome expression profiling.
Methods: DNA microarray-based gene expression and histoclinical data of 2515 early BCs from thirteen datasets
were collected. We searched for a kinome-based GES associated with disease-free survival (DFS) in basal BCs of the
learning set using a metagene-based approach. The signature was then tested in basal tumors of the independent
validation set.
Results: A total of 591 samples were basal. We identified a 28-kinase metagene associated with DFS in the
learning set (N = 73). This metagene was associated with immune response and particularly cytotoxic T-cell
response. On multivariate analysis, a metagene-based predictor outperformed the classical prognostic factors, both
in the learning and the validation (N = 518) sets, independently of the lymphocyte infiltrate. In the validation set,
patients whose tumors overexpressed the metagene had a 78% 5-year DFS versus 54% for other patients (p =
1.62E-4, log-rank test).
Conclusions: Based on kinome expression, we identified a predictor that separated basal BCs into two subgroups
of different prognosis. Tumors associated with higher activation of cytotoxic tumor-infiltrative lymphocytes
harbored a better prognosis. Such classification should help tailor the treatment and develop new therapies based
on immune response manipulation.
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Background
Breast cancer (BC) is heterogeneous. Gene expression
profiling has identified molecular subtypes with different
biological features and different outcome [1-5], includ-
ing basal BCs. Basal BCs, which represent ~15-20% of
invasive BCs are high-grade tumors, frequently do not
express hormone receptors (HR) and ERBB2, and have
the worst prognosis overall [6,7]. Yet, basal tumors show
prognostic heterogeneity. Both the standard histoclinical
features and the recently defined prognostic gene
expression signatures (GES) fail to identify patients who
will relapse and patients who will not respond to che-
motherapy [8]. Defining the molecular bases of this het-
erogeneity should help better understand these tumors,
identify new therapeutic targets and more reliable pre-
dictors of survival and therapeutic response.
Kinases, which constitute ~1.7% of human genes [9],
are activated or overexpressed in cancers [10], and con-
stitute current or future targets for successful therapies
[11]. Previously, we identified a 16-kinase GES that
improved the prognostic classification of luminal BCs
[12]. A similar approach was successfully applied to 44
estrogen receptor (ER)-negative BCs, including ERBB2-
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positive tumors and less than 50% of basal tumors [13].
To our knowledge, the “kinome approach” has never
been applied to basal BCs only.
We tested the hypothesis that the expression of kinase
genes may distinguish good- from poor-prognosis basal
tumors.
Methods
Patients’ selection
Institut Paoli-Calmettes (IPC) and public retrospective
data sets from BC samples profiled using oligonucleotide
microarrays were collected (Additional file 1, Table S1).
All were pre-treatment samples of invasive non-inflam-
matory and non-metastatic adenocarcinomas. Microar-
ray data from our set are available through Gene
Expression Omnibus (series entry GSE21653).
The “IPC” training set included 261 patients who
underwent initial surgery in our institution between
1992 and 2007. Each patient gave written informed con-
sent and this study has been approved by our institu-
tional ethics committee. All samples were histologically
reviewed in a standardized fashion by a pathologist (JJ)
to asses the ER, progesterone receptor (PR) and ERBB2
status by immunohistochemistry (IHC), and the percent
of cancer cells (superior to 60%). Antibodies used
(Dak®) were SP1 clone for ER, PgR636 clone for PR and
Herceptest™ for ERBB2. The cut-off for positivity was
1% of stained tumor cells for HR, and ERBB2 status (0-
3+ score, DAKO HercepTest kit scoring guidelines) was
defined as positive if 3+ or 2+ with amplification con-
firmed by in situ hybridization. Vascular invasion and
lymphocytic infiltration were assessed by Hematoxylin
and Eosin Staining (HES).
Twelve pooled public data sets constituted the valida-
tion set including a total of 2254 samples [5,7,14-23].
DFS was the best annotated survival information among
these sets and was chosen as survival end-point.
Gene expression data analysis
Details are given in Additional file 2 (Supplementary
Material). Data sets were processed as previously
described [24]. Briefly, for the Agilent sets, we applied
quantile normalization to available processed data.
Regarding the Affymetrix sets, we used Robust Multi-
chip Average (RMA) with the non-parametric quantile
algorithm as normalization parameter [25]. Quantile
normalization or RMA was done in R using Bioconduc-
tor and associated packages. The five molecular subtypes
were determined using the single sample predictor (SSP)
classifier [26].
Other analyses were centered on 771 kinase and
kinase-interacting genes, based on an update of the
initial kinome description [9,13]. This list was matched
with genes available on the Affymetrix U133 Plus 2.0
microarrays used to profile the IPC tumor set, finally
retaining 661 genes (Additional file 3, Table S2). Ana-
lyses were both unsupervised and supervised. Supervised
t-test analysis searched for genes upregulated in basal
samples compared to at least one of the four other
molecular subtypes, with 5% significance and a false dis-
covery rate (FDR) lower than 5%. To circumvent the
problem of dissymmetry of variables with a number of
samples inferior to the number of genes being tested
[14,27-31], we grouped the resulting genes with corre-
lated and interdependent expression (gene subsets) in a
single “metagene”. Metagene expression value is the
mean of the normalized expression values of all genes in
the respective gene subset. Each metagene is treated as
if it were a single gene, thereby reducing data dimen-
sion. We defined our metagenes by hierarchical cluster-
ing using data median-centered on genes, Pearson
correlation as similarity metrics and centroid linkage
clustering [32]. We identified robust gene clusters (mini-
mal cluster size and minimal Pearson correlation were
15 and 0.6, respectively) using the quality-threshold
(QT) clustering method [32]. A metagene was then
computed for each selected cluster, and its prognostic
incidence (as continuous value) evaluated using a Cox
regression univariate analysis. Once a metagene asso-
ciated with DFS (5% level significance) was defined, its
expression value was used to divide the training set into
two subgroups then tested for association with DFS.
The cut-off was defined as the best threshold dividing
the population into two subgroups with the greater DFS
difference, “Metagene-Low” (expression value inferior to
the threshold) and “Metagene-High” (expression value
above) subgroups. This cut-off was applied to basal
tumors of each validation series, and the define sub-
groups were then pooled before prognostic analysis.
We tested the prognostic value of two recently
reported classifiers associated with survival in basal BCs:
the medullary BC (MBC) classifier [33] and the HER2-
derived prognostic predictor (HDPP) [34] associated
with survival in both ERBB2+ and basal tumors. We
also tested three multigene signatures identified as prog-
nostic in breast cancer, independently of molecular sub-
types: the Genomic Grade Index [16], the 76-gene
signature [15], and the 70-gene signature [5]. Ontology
analysis was done using Ingenuity Pathway Analysis
(IPA) software (Redwood City, CA, USA) [35]. We also
determined if immune signatures [36] were overrepre-
sented in one prognostic subgroup using the gene set
enrichment analysis (GSEA) algorithm and 1000 permu-
tations [37].
Statistical analysis
Correlations between sample groups and histoclinical
factors were calculated with the Fisher’s exact test and
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the t-test when appropriate. DFS was calculated from
the date of diagnosis until date of first relapse or death
using the Kaplan-Meier method, and follow-up was
measured to the date of last news for event-free
patients. Survival curves were compared with the log-
rank test. Univariate and multivariate prognostic ana-
lyses used the Cox regression method. Univariate ana-
lyses tested classical histoclinical factors: age (≤50 years
vs. > 50), pathological tumor size (pT≤20 mm vs. > 20),
lymph node status (pN positive vs. negative), SBR grade
(I vs. II-III), IHC ER status (negative vs. positive), peritu-
moral vascular invasion (negative vs. positive) and lym-
phocytic infiltrate. Data regarding the delivery of
adjuvant chemotherapy and hormone therapy were also
analyzed. Analyses included also binary classifications
based on the immune metagene, the MBC and HDDP
classifiers (good vs. poor-prognosis subgroups). Multi-
variate analyses tested all variables with a p-value infer-
ior to 0.05 in univariate analysis and excluded patients
with one or more missing data. All statistical tests were
two-sided at the 5% level of significance. Analyses were
done using the survival package (version 2.30), in the R
software (version 2.9.1). Our analysis adhered to the
reporting recommendations for tumor marker prognos-
tic studies (REMARK) [38].
Results
Identification of a prognostic kinase expression signature
Five hundreds and ninety-one out of 2515 tumors were
basal, including 73/261 in our IPC series and 518/2254
in the public sets (Table 1). These tumors displayed
classical histoclinical features of basal BC (Additional
file 4, Table S3). Clinical outcome, available for 2109
patients, correlated with subtypes with 5-year DFS of
83% for luminal A, 60% for luminal B, 77% for normal-
like, 61% for basal, and 61% for ERBB2-overexpressing.
The 73 IPC basal tumors were used as training set for
identifying a prognostic kinase GES from the 661-gene
list. Supervised analysis identified 581 genes differen-
tially expressed in basal versus at least one other sub-
type, including 360 genes overexpressed in basal tumors
(Additional file 3, Table S2). Within this series most of
the patients (90%) received adjuvant chemotherapy.
Twenty-five patients developed relapse or death with a
median time-to-relapse of 19 months, and forty-eight
patients remained disease-free with a median follow-up
of 64 months. The 5-year DFS was 63%. Hierarchical
clustering of these tumors with the 360-gene set (Figure
1A) revealed two main clusters, I (n = 24) and II (n =
49), with 5-year DFS superior in cluster I (77% versus
56%; p = 0.22, log-rank test; Figure 1B). QT clustering
identified three gene clusters with a major role in this
discrimination (Figure 1A, and Additional file 5, Table
S4). One included 21 genes not related to any specific
biologic function. A second cluster was associated with
the cell cycle. The third cluster (thereafter designed
immune cluster) contained 28 genes, which for many
were involved in immune signaling (e.g. BLK, BTK,
FYN, SYK, ITK, JAK3, LCK, LCP2, PRKCB, and ZAP70).
Visually, lower expression of this cluster was associated
with more relapses (Figure 1A). We built a metagene
for each gene cluster, and analyzed their correlation
with DFS using univariate Cox regression analysis. Only
the immune metagene correlated with DFS (HR = 0.32,
Table 1 Histoclinical features of basal-like tumors (IPC
and validation series)
Characteristics (N) Basal
N = 591
N (% of evaluated cases)
Age (445)
≤ 50 years 215 (57%)
> 50 years 162 (43%)
Histological type (256)
ductal 234 (91%)
lobular 7 (3%)
other* 15 (6%)
Pathological tumor size, pT (466)
pT1 115 (25%)
pT2-4 351 (75%)
Pathological lymph node status, pN (493)
negative 314 (64%)
positive 179 (36%)
Tumor grade (493)
SBR 1 14 (3%)
SBR 2-3 479 (97%)
IHC ER status (507)
negative 411 (81%)
positive 96 (19%)
IHC PR status (223)
negative 199 (89%)
positive 24 (11%)
IHC ERBB2 status (105)
negative 86 (84%)
positive 19 (16%)
Adjuvant chemotherapy (309)
no 203 (66%)
yes 106 (34%)
Adjuvant hormone therapy (322)
no 237 (95%)
yes 13 (5%)
Events (453)** 183 (40%)
5-year DFS (453)** 61%
*4 metaplastic carcinomas, 4 mixed adenocarcnomas, 1 mucinous carcinoma,
and 5 adenocarcinomas non otherwise specified. **out of these 453 patients
with available follow-up, 193 did not received any systemic adjuvant
treatment, 115 received adjuvant systemic therapy, no patient received
adjuvant Trastuzumab, and data were unavailable for 145 patients.
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95%CI [0.17-0.68], p = 2.4E-3, Wald test; Additional file
6, Table S5). Resampling with 100,000 iterations showed
only a 0.8% probability to find a metagene built from 28
random genes with similar or better prognostic correla-
tion than the immune metagene.
We defined two subgroups of basal tumors according
to the immune metagene expression value: “Immune-
High” if above the value threshold (n = 25) and
“Immune-Low” if under (n = 48). No histoclinical fac-
tor including the lymphocyte infiltrate was different
between the two subgroups (Additional file 7, Table
S6). Survival was different, with 91% 5-year DFS in
“Immune-High” subgroup versus 49% in “Immune-
Low” (p = 0.005, log-rank test, Figure 2). On univariate
analysis (Table 2), two factors were associated with
DFS: vascular invasion (HR = 2.32, 95%CI [1.04-5.18],
p = 0.04, Wald test) and immune metagene expression
(HR = 0.21, 95%CI [0.06-0.70], p = 0.01, Wald test).
They remained significant on multivariate analysis
(Table 2).
We also performed a similar analysis on genes underex-
pressed in basal tumors, but it did not allow the identifi-
cation of any robust gene clusters.
Validation of the prognostic signature
The expression of the immune metagene was studied in
the independent panel of 518 basal tumors not used to
define the predictor. Follow-up for DFS was annotated
for 380 patients: 158 developed relapse or death with a
median time-to-relapse of 30 months, and 222 remained
disease-free with a median follow-up of 93 months. The
5-year DFS was 60%. At least 25 out of 28 (mean = 27)
genes included in the immune metagene were common
to each separate set (Additional file 1, Table S1). A total
of 122 patients were defined as “Immune-High” and 396
as “Immune-Low”. Their histoclinical features (including
A
Relapses
I II
3 -30
B
Cluster I
Cluster II
77%
56%
p = 0.22, log-rank test
0 24 48 72 9612 36 60 84
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Figure 1 Hierarchical clustering of basal breast cancer. (A) Unsupervised hierarchical clustering of 73 non-metastatic non-inflammatory basal
BCs from IPC with 360 genes coding for kinase or kinase-interacting proteins overexpressed in basal tumors. Each row represents a gene and
each column a sample. The expression level of each gene in each sample is relative to its median abundance across the samples and is
depicted according to the color scale shown under the matrix. Red and green indicate expression levels respectively above and below the
median. Relapses are indicated in the stripe under the dendrogram: white for no relapse during follow-up, and grey for relapse. Two tumor
clusters (I and II) are delineated by the vertical green line. To the right, vertical colored bars indicate the three clusters identified by the QT
clustering method: purple, immune-related cluster; green, biologically unspecific cluster; red, proliferation-related cluster. (B) Kaplan-Meier disease-
free survival curves for cluster I patients (n = 24), and cluster II patients (n = 49).
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the lymphocyte infiltrate available in 56 out of 518
tumors) were well balanced, except SBR grading, more
frequently II-III in the “Immune-High” subgroup (Table
3). The 5-year DFS was 78% in the “Immune-High” sub-
group and 54% in the “Immune-Low” one (p = 1.62E-
04, log-rank test, Figure 3A), confirming the prognostic
value of the immune metagene. Analysis by data set
showed that the mean difference of 5-year DFS between
“Immune-high” and “Immune-low” cases was 25% (95%
CI, [13 - 37], p = 0.0038, T-test).
On univariate analysis (Table 4), two factors correlated
with DFS: lymph node involvement (HR = 1.53, 95%CI
[1.04-2.25]; p = 0.03, Wald test) and immune metagene
expression (HR = 0.45, 95%CI [0.29-0.69]; p = 2.9E-04, Wald
test). On multivariate analysis, both remained significant.
Comparison with existing classifiers
Two prognostic multigenic models have been reported
in basal BC: the MBC and HDPP classifiers [33,34]. We
assessed their prognostic value in the present 518 basal
tumors. On univariate analysis, the MBC classifier corre-
lated with DFS, with a HR for relapse of 0.59 (95% CI
[0.43-0.82], p = 0.0017) for good-prognosis patients as
compared with poor-prognosis patients. In multivariate
analysis including this classifier, our immune metagene
classifier and lymph node status showed that both geno-
mic classifiers were significant, whereas node involve-
ment was not (Table 4), suggesting that the multigenic
models have independent prognostic value. The HDPP
classifier confirmed its prognostic value for ERBB2-over-
expressing tumors in our series (n = 214), but not in
the 518 basal samples: 5-year DFS was 63% for the
good-prognosis patients versus 61% for the poor-prog-
nosis patients (p = 0.62, log-rank test).
We also assessed the prognostic impact of three pub-
lished major prognostic expression signatures recently
reported in early breast cancer. In each data set, each
sample was assigned a good or a poor prognosis based
on each signature. Data sets were then pooled, and sur-
vival was compared between the predicted good-prog-
nosis and poor-prognosis subgroups. Univariate DFS
analysis performed in the basal subtype showed that
none of these classifiers was associated with survival
(Table 5). These results show the absence of informative
value of these signatures in the basal subtype, by con-
trast with our classifier.
Prognostic and/or predictive value of the immune
classifier?
To determine the link of the immune metagene with
metastatic risk and/or with response to chemotherapy,
we analyzed - within the series of 518 basal BCs - the
187 cases with available follow-up who had not received
Immune-High
Immune-Low
91%
49%
p = 0.005, log-rank test
0 24 48 72 9612 36 60 84
0,0
0,2
0,4
0,6
0,8
1,0
Figure 2 Disease-free survival and basal subgroups in the
learning set. Kaplan-Meier disease-free survival curves of basal BC
patients in the IPC series according to the subgroups “Immune-
High” (n = 25) and “Immune-Low” (n = 48).
Table 2 Univariate and multivariate analyses by Cox regression of basal tumors, IPC series
Univariate Analysis Multivariate Analysis
N HR [95% CI] p-value N HR [95% CI] p-value
Age ≤50 (vs > 50 y) 73 1.83 [0.79-4.26] 0.16
pT > 20 mm (vs ≤ 20 mm) 73 1 [0.96-1.05] 0.95
pN pos (vs neg) 73 1.93 [0.88-4.24] 0.1
Grd 2-3 (vs 1)* 73 0.15 [0.02-1.18] 0.07
ER pos (vs neg) 73 1.08 [0.25-4.68] 0.91
Vascular invasion 72 2.32 [1.04-5.18] 0.04 72 2.30 [1.03-5.14] 0.04
Lymphocyte infiltrate ** 71 0.38 [0.11-1.28] 0.12
Chemotherapy 73 0.62 [0.18-2.12] 0.62
Hormone therapy 72 1.76 [0.64-4.81] 0.27
Immune metagene High (vs Low) 73 0.21 [0.06-0.70] 0.01 72 0.22 [0.07-0.73] 0.01
* Only 1 tumor was grade 1
**absent to low vs moderate to high.
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any adjuvant systemic therapy. In this set, “Immune-
High” patients had a longer DFS than “Immune-Low”
patients with 5-year DFS of 82 vs. 55% respectively (p =
4.75E-03, log-rank test; Figure 3B).
Next, we studied the capacity of our model to predict
pathological complete response (pCR) after anthracy-
cline-based neoadjuvant chemotherapy. Information was
available for two data sets with the following regimens:
weekly paclitaxel and fluorouracil-doxorubicin-cyclopho-
sphamide (55 patients with pCR and 70 without) [22],
and fluorouracil-epirubicin-cyclophosphamide or doce-
taxel followed with docetaxel-epirubicin (34 patients
with pCR and 99 without) [23]. We identified 98 basal
cases out of the 258 included samples. “Immune-High”
patients experienced more pCR (59%) than “Immune-
Low” patients (43%), but the difference was not signifi-
cant (Odds ratio = 1.87, 95%CI [0.57-6.40], p = 0.29,
Fisher’s exact test).
Altogether, these observations suggested that the
immune metagene is associated with relapse risk,
whereas its association with response to chemotherapy
deserves to be tested in larger series.
The immune kinase metagene correlates with cytotoxic T-
cell response
We next sought to elucidate the type of immune
response associated with our metagene. Ontology analy-
sis of the 28 genes using IPA software confirmed asso-
ciation with many pathways involved in immune
response [35], particularly in lymphocyte activation pro-
cesses, such as “T-cell receptor signaling”, “CD28 signal-
ing in T helper cells”, “NK cell signaling”, “PLC
signaling”, “Role of NFAT in regulation of the immune
response”, “NF-kB signaling”, or “IL2 signaling” (Addi-
tional file 8 - Table S7, and Additional file 9 - Figure
S1). The upregulation of BTK, CD3E, FYN, ITK, LCK,
Table 3 Histoclinical comparison of the two basal subgroups defined with the immune metagene in the independent
validation series
Characteristics (N) Immune-High n = 122 Immune-Low n = 396 p-value OR (95%CI)
N (% of evaluated cases)
Age (372) 0.71*
≤ 50 years 53 (62%) 169 (59%) 1
> 50 years 33 (38%) 117 (41%) 1.11 (0.66-1.89)
Pathological tumor size, pT (394) 0.11*
pT1 32 (33%) 73 (24%) 1
pT2-4 64 (67%) 225 (76%) 1.54 (0.9-2.6)
Pathological lymph node status, pN (420) 0.90*
negative 62 (65%) 208 (64%) 1
positive 33 (35%) 117 (36%) 1.06 (0.64-1.77)
Tumor grade (420) ND
SBR 1 0 (0%) 13 (4%)
SBR 2-3 103 (100%) 304 (96%)
IHC ER status (434) 0.57*
negative 73 (77%) 269 (79%) 1
positive 22 (23%) 70 (21%) 0.86 (0.49-1.57)
Lymphocyte infiltrate (56) 0.51*
absent 6 (46%) 14 (33%) 1
present 7 (54%) 29 (67%) 1.76 (0.41-7.48)
Adjuvant chemotherapy (354) 0.43*
no 49 (64%) 162 (58%) 1
yes 28 (36%) 115 (42%) 1.24 (0.72-2.18)
Adjuvant hormone therapy (269) 0.11*
no 59 (91%) 197 (97%) 1
yes 6 (9%) 7 (3%) 0.40 (0.12-1.46)
Follow-up (months, median) (380) 95 89 0.44**
Relapses (380) 25 (26.3%) 133 (46.7%) 4.77 E-04* 0.41 (0.23-0.70)
5-year DFS (380) 78% 54% 1.6 E-04***
N, number of tumor samples - out of the 2515 samples - with available information for the corresponding characteristic, *, Fisher’s exact test; **, Mann-Whitney
test; ***, log-rank test; ND, not done.
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LCP2, PRKCs, SYK, ZAP70 and JAK3 clearly identified
an activated profile of the lymphocytic lineage.
To better explore the molecular differences between
“Immune-High” and “Immune-Low” basal BCs, we
searched for the genes differentially expressed between the
two subgroups in the IPC series using the whole genome
and not only the kinome. Supervised analysis (0.1% FDR)
identified 532 differential genes. Most of them (n = 506)
were overexpressed in “Immune-High” samples (Additional
file 10, Table S8A). Ontology analysis showed that these
genes were particularly involved in immune response, and
more specifically in adaptive immunity (Additional file 10,
Table S8B). To confirm this observation, we applied GSEA
using reported T-cell, CD8+ T-cell and B-cell expression
signatures [36]. As shown in Additional file 11 (Figure S2),
an enrichment of genes involved in T-cell, CD8+ T-cell and
B-cell signatures was found in “Immune-High” cases.
Discussion
Basal BCs are poor-prognosis tumors, which require
both improvement of our ability to predict the clinical
outcome for better tailoring treatment and identification
of new therapeutic targets. Their prognosis is heteroge-
neous, and it is currently impossible to predict which
patients will or will not relapse using classical histoclini-
cal factors or the recently reported prognostic GES,
notably those currently tested in clinical trials [39]. In
the same way, the HDDP classifier [34] identified using
ERBB2+ tumors, failed to classify basal samples. Prog-
nostic analyses should be done per subtype [40].
Analysis of kinase and kinase-related genes might help
develop new targeted therapies. We report a kinase-
based model that divides basal BCs into two subgroups
with balanced histoclinical factors but different survival
(25% difference for 5-year DFS). This model is based on
the expression of an immune 28-gene metagene. Identi-
fied in a learning set, its prognostic value was confirmed
in an independent data set of 518 cases. The model out-
performed the individual current prognostic factors on
multivariate analysis, both in the learning and validation
sets. Patients with high expression of the immune meta-
gene had a better DFS than other patients. This prog-
nostic value remained when applied to patients treated
without any adjuvant chemotherapy, suggesting a link
with the metastatic potential. An additional link with
chemosensitivity cannot be excluded as “Immune-High”
patients experienced a higher, but non significant, pCR
rate than “Immune-Low” patients.
The favorable prognostic impact of the immune
response, particularly the T-cell response, has been
reported in ER-negative [8,13,14,26,41-43] or ERBB2+
BCs [8,28,31,44]. Similar finding was reported in 97 tri-
ple-negative BCs [45] in which increased expression of
interferon-related genes tended to confer better prog-
nosis. In our previous study [33] and the present one,
we focused on basal BC only, since this subtype is even
more homogeneous than the triple-negative group [46].
In our previous study, we defined a 368-gene prognosti-
cator, which confirmed the positive influence of TH1
Table 4 Univariate and multivariate (with and without MBC-based classifier) DFS analyses by Cox regression of basal
tumors: public series
Univariate Analysis Multivariate Analysis*
N HR [95%CI] p-value N HR [95%CI] p-value HR [95%CI] p-value
Age ≤ 50 (vs > 50y) 253 0.96 [0.65-1.41] 0.84
pT > 20 mm (vs ≤ 20 mm) 275 1.40 [0.93-2.11] 0.11
pN pos (vs neg) 301 1.53 [1.04-2.25] 0.032 301 1.58 [1.07-2.33] 0.021 1.46 [0.99-2.16] 0.06
Grd 2-3 (vs 1) 302 3.00 [0.74-12.1] 0.12
ER pos (vs neg) 315 0.68 [0.45-1.03] 0.07
Chemotherapy 236 1.28 [0.77-2.14] 0.34
Hormone therapy 250 1.01 [0.41-2.48] 0.98
MBC-based classifier 380 0.59 [0.43-0.82] 1.72 E-04 301 0.59 [0.40-0.87] 7.5 E-03
Immune metagene High (vs Low) 380 0.45 [0.29-0.69] 2.4 E04 301 2.15 [1.32-3.50] 0.0022 0.54 [0.33-0.89] 0.015
* multavariate analyses were performed without (left) and with (right) the medullary-based classifier.
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Figure 3 Disease-free survival and basal subgroups in the
validation set. Kaplan-Meier disease-free survival curves of basal BC
patients in the independent validation series according to the
subgroups “Immune-High” and “Immune-Low”. (A) in all patients (95
versus 285 patients respectively), and (B) in patients having received
no systemic adjuvant therapy (39 versus 148 patients respectively).
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cells and high cytotoxic activity. This model outper-
formed two immune signatures in multivariate analysis
of DFS [28,42]. We showed here that both the immune
kinase model and this previous model maintain their
prognostic value in multivariate analysis, suggesting
their independence. It is of note that our “immune-
metagene” model presented a prognostic value in lumi-
nal B (p = 0.03, Wald test) and ERBB2-overexpressing
cases (p = 0.02, Wald test), but not in luminal A and
normal-like samples (p = 0.58 and 0.98, respectively,
Wald test). Moreover, it is worth noting that previously
published signatures (Genomic grade index, 70-gene sig-
nature, and 76-gene signature), mainly based on prolif-
eration, failed to separate good from poor prognosis
basal breast cancers.
Ingenuity analysis of both the 28 genes and the genes
differentially expressed between the two subgroups
defined by our kinase immune metagene confirmed that
the differences between these histoclinically similar sub-
groups are in immune genes. Upregulated kinome-genes
suggest the presence of an activated lymphocyte infil-
trate in “Immune-High” patients. This lymphocyte-acti-
vated status is due to stimulations by cytokines (JAK3,
STAT1, STAT4, TBX21 and TH1 cytokine receptors),
by T-cell receptor (T-cell receptor chains [alpha, beta
and gamma], CD3E, CD3D, CD247/CD3Z, CD28, CD27,
CD2, CD8A, CD4, LAG3, MAL, LAT2, PIM2), by B-cell
receptor (CD19, CD79b, CD27, CD40, IGJ, IGK@,
IGH@, BTK, BLNK, BANK1), and by anti-tumor recep-
tors (KLRK1, KLRB1, GAB3, SLAMF1, SLAMF6-8). The
lymphocyte infiltrate is strictly TH1-biased with the
overexpression of IL2RG, IL23RB and IL7R involved in
lymphocyte survival, of IL12RB1, IL15RA, IL18BP, and
IL21R TH1-biased receptors, of STAT1, STAT4, and
TBX21 TH1 transcription factors, and of several inter-
feron-inducible molecules (GVIN1, ISG20, GBP2, IRF1,
IRF4, IRF7, and IRF8). This agrees with increased levels
of cytotoxic granules and pore-forming molecules
(VAMP1, GZMA, GZMB, GZMH, GZMK, GNL, PRF1,
CFLAR, CASP1, and CASP10). Interestingly, there are
also several genes encoding activated memory lympho-
cyte recruitment such as IL16, XCL1, CCL5, CCR5,
CXCL9, CXCR3, CCL19, CCR7, and CXCR6 (mostly
helper and cytotoxic T-cells), and CXCL13, CXCR5
(activated B-cells), among which some are strictly pro-
duced by activated T-cells, such as CCL4 and CCL5.
Finally, we also found transcripts involved in lymphocyte
migration and/or activation (ITGAL and ITGB2 hetero-
dimers, ITGA4, ITGAX, ITGB7, SELL, SELP, SELPL,
and CD69).
Thus, we show that the immune response, and notably
the adaptive cytotoxic TH1-cell response [47], influence
survival of basal BC patients. Despite the small size of
the independent population with lymphocyte infiltrate
data available, which does not allow to really conclude
about the impact of the quantity of lymphocyte infiltrate
on the expression of immune response-related genes,
the absence of correlation between the immune meta-
gene and lymphocyte infiltration in our cohort and in
two independent data sets [5,8] as well as the function
of genes, suggest that this influence does not depend on
the degree of lymphocyte infiltrate, but on the efficiency
of its cytotoxic activation status. The differential expres-
sion of these “immune genes” is probably also due to a
variable expression of epithelial-derived molecules
[13,42,48], which activate (in “Immune-High” cases) or
repress (in “Immune-Low” cases) the local immune
response to the tumor. These hypotheses deserve further
investigation to understand the respective role of tumor-
infiltrative lymphocytes and cancer cells on cancer
history.
Conclusions
In conclusion, we propose a robust prognostic subdivi-
sion of basal BC based on the expression of 28 genes,
involved in immune response and notably the cytotoxic
T-cell response. Tumors associated with higher activa-
tion of cytotoxic tumor-infiltrative lymphocytes have a
better prognosis, and are likely to better respond to che-
motherapy. Such classification should help tailor treat-
ment. Furthermore, since adaptive immunity seems to
play a pivotal role [49] immune response manipulation
might be an efficient way of treating or preventing these
poor-prognosis tumors [47,50].
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Additional file 1: Table S1: Description of the breast cancer data
sets.
Additional file 2: Supplementary materials.
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features of the pooled data sets.
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identified with QT clustering.
Additional file 6: Table S5: Univariate DFS analysis of metagenes by
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Table 5 Comparison of the prognostic value of the
immune-metagene classifier with three available
signatures, Disease-free survival, Cox univariate analysis
N HR [IC95] p-value
Immune-metagene High vs Low 380 2.23 [1.45-3.42] 2.4 E-04
70-gene signature Poor vs Good 380 1 [1] NaN*
Genomic grade index High vs Low 380 1.30 [0.53-3.18] 0.56
76-gene signature Poor vs Good 317 1.40 [0.96-2.03] 0.08
*all basal tumors were classifeid as “poor prognosis” by this classifier.
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Additional file 7: Table S6: Histoclinical comparison of the two
basal subgroups defined with the immune metagene (IPC series).
Additional file 8: Table S7: Ingenuity canonical pathways associated
with the immune-related cluster.
Additional file 9: Figure S1: Biological network of genes included in
or associated with our 28-gene model. A fine-tuning between
inhibitor (phosphatases) and activator (kinases) signals regulates
lymphocyte anti-tumor immunity. AK and Pyk2 are two of the major
kinases that become tyrosine phosphorylated following lymphocyte
stimulation. Both are associated to Lck. Lck (lymphocyte specific kinase)
and Fyn are cytoplasmic tyrosine kinases of the Src family expressed in T-
cells and natural killer (NK) cells, under the T cell receptor (TCR) or
Natural cytotoxicity receptor (NCR). Their activity is critical for T and NK
cell receptors-mediated signaling, leading to normal T- and NK-cell
development and activation. Increased Fyn transcript and protein
content in T cells can be observed with high T cell activity. Square 1. LAT
is a linker protein essential for activation of T lymphocytes. Its rapid
tyrosine-phosphorylation upon TCR stimulation recruits downstream
signaling molecules for membrane targeting and activation. LAT is a
substrate for Syk/Zap70 kinase and an immediate substrate for both Lck
and Syk kinases. Its phosphorylation is an early event leading to T-cell
activation. Both Lck and Syk phosphorylate the ITAM-like motifs on LAT,
which is essential for induction of the interaction of LAT with
downstream signaling molecules such as Grb2, PLC-g1 and for activation
of MAPK-ERK pathways. ZAP70 is thus at the crossroad of several
signaling pathways that control lymphocyte development and function
and cell survival in response to a wide variety of activator signals coming
from the NCR, TCR or other receptor involved in anti-tumor immunity.
Square 2. Cytokines receptors express at the membrane also regulate
lymphocyte activation through the JAK-STAT signaling pathway. Square
3. In B, T and NK cells, the inhibition of these kinases is mostly mediated
by protein tyrosine phosphatases (PTP), regrouping members of the SHP
family (SHP-1, SHP-2) or LYP family. These proteins inhibit effector phase
functions by dephosphorylating a wide spectrum of phospho-proteins
involved in hematopoietic cell signaling.
Additional file 10: Table S8: Genes differentially expressed between
the “Immune-High” and “Immune-Low” basal tumor subgroups in
the IPC set. (A) Summary of the 532 genes differentially expressed
(Student’s t-test). (B) Canonical pathways associated with the genes
overexpressed in “Immune-High” tumors in the IPC set.
Additional file 11: Figure S2: Correlation of basal breast cancer
subgroups (IPC series) and leukocyte cell-type gene expression
signatures (GSEA algorithm). (A) Results of GSEA with the three tested.
NES, normalized enrichment score; FDR, false discovery rate. (B)
Enrichment plots for the three significant signatures: T-cell, CD8+ T-cell,
and B-cell (from left to right).
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